Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Director comp.
Quarterly results
TREVENA INC (TRVN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "TREVENA, INC. Condensed Statements of Operations Three Months Ended Jun 30, Six Months Ended Jun 30, 2023 2022 2023 2022 Product revenue $ 21 $ - $ 27 $ - License revenue 3,000 - 3,000 20 Total revenue 3,021 - 3,027 20 Operating expenses: Cost of goods sold 88 216 214 423 Selling, general and administrative 5,138 10,306 11,227 21,320 Research and development 3,991 4,291 7,900 9,550 Total operating expenses 9,217 14,813 19,341 31,293 Loss from operations Other income 483 Net loss $ $ $ $ Per share information: Net loss per share of common stock, basic and diluted $ $ $ $ Weighted average shares outstanding, basic and diluted 11,580,128 6,621,083 10,592,586 6,620,942 TREVENA, INC. Condensed Balance Sheets"
07/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/20/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
07/20/2023 8-K Quarterly results
07/17/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
07/17/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
07/17/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
07/17/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
07/17/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
07/17/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
07/17/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
07/17/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
07/17/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
07/17/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
07/17/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
07/17/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
07/06/2023 8-K/A Submission of Matters to a Vote of Security Holders  Interactive Data
06/30/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/28/2023 4 Shin Barry (SVP, CFO) has filed a Form 4 on TREVENA INC
Txns: Paid exercise price by delivering 722 shares @ $0.84, valued at $606.5
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 8-K Quarterly results
Docs: "TREVENA, INC. Condensed Statements of Operations Three Months Ended Mar 31, 2023 2022 Product revenue $ 6 $ - License revenue - 20 Total revenue 6 20 Operating expenses: Cost of goods sold 127 207 Selling, general and administrative 6,089 11,014 Research and development 3,909 5,259 Total operating expenses 10,125 16,480 Loss from operations Other income 2,300 71 Net loss $ $ Per share information: Net loss per share of common stock, basic and diluted $ $ Weighted average shares outstanding, basic and diluted 9,594,072 6,620,800 TREVENA, INC. Condensed Balance Sheets",
"CLIN PHASE 1 PHASE 2 PHASE 3 NDA POST"
05/09/2023 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Trevena to Release First Quarter 2023 Financial Results on May 15, 2023"
05/09/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "About OLINVYK® injection OLINVYK is a new chemical entity approved by the FDA in August 2020. OLINVYK contains oliceridine, an opioid, which is a Schedule II controlled substance with a high potential for abuse similar to other opioids. It is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. OLINVYK is available in 1 mg/1 mL and 2 mg/2 mL single-dose vials, and a 30 mg/30 mL single-patient-use vial for patient-controlled analgesia . Approved PCA doses are 0.35 mg and 0.5 mg and doses greater than 3 mg should not be administered. The cumulative daily dose should not exceed 27 mg. Please see Important Safety Information, including the BOXED WARNING, and full prescribing information..."
04/21/2023 8-K Quarterly results
03/30/2023 10-K Annual Report for the period ended December 31, 2022
03/30/2023 8-K Quarterly results
03/30/2023 8-K Quarterly results
03/13/2023 8-K Other Events  Interactive Data
02/14/2023 SC 13G ARMISTICE CAPITAL, LLC reports a 10% stake in Trevena, Inc.
01/09/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Presentation Deck",
"TRV045 Overview Deck",
"Company Contact:"
01/06/2023 4 Shin Barry (SVP, CFO) has filed a Form 4 on TREVENA INC
Txns: Granted 50,000 shares @ $0
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy